Memorial Sloan Kettering Cancer Center
The purpose of this study to learn more about the use of redifferentiating medications as a standard treatment for radioactive iodine/RAI-refractory thyroid cancer. This study is a registry study.
Inclusion Criteria: * Patients ≥ 18 years old at time of consent Inclusion Criteria: * Patients diagnosed with RAI refractory thyroid cancer or unlikely to respond to RAI. * Patients who will receive redifferentiation agents prior to planned diagnostic and/or therapeutic use of radioactive iodine as part of routine clinical care. * Patients who have never received redifferentiation agents outside of a clinical trial or have received redifferentiation agents in the context of a clinical trial will be enrolled after the clinical team has decided to proceed with a redifferentiation agent as pa…
Follow-up visits will be carried out at intervals per usual clinical practice. Tolerance of medication and adverse events will be recorded in every visit.
Arctuva estimate
Verify or correct the compensation shown for this listing.